Company Intelligence Profile
Gosamplify Private Limited
Home sample-collection logistics platform (brand "Samplify") connecting diagnostic labs/healthcare providers with patients for at-home specimen pickup, headquartered in Gurugram, Haryana.
Last updated 17 August 2026
AI-generated summary from public filings and may contain errors. Verify against the detailed sections below.
See what AICA knows about Gosamplify
Deeper analysis, financial signals and peer comparisons.
Company Identity
Confirmed| Registered name | Gosamplify Private Limited |
|---|---|
| CIN | U85100HR2021PTC093209 |
| PAN | AAICG8716G |
| Status | Active |
| Listing | Not listed / unlisted private limited company |
| Incorporated | 26 February 2021 |
| ROC | Conflict: Tofler states RoC-Haryana |
| Sector (NIC) |
|
| Registered address |
|
| Authorized capital | INR 49 Lakh |
| Paid-up capital | Conflict: Tofler shows ₹36.3 Lakh |
Business Overview
Confirmed- GoSamplify (brand "Samplify") is a healthcare-logistics company providing home/at-home sample (specimen) collection and transport for diagnostic labs and healthcare providers across India
- Per the company's own site (fetched via reader proxy): "end-to-end transparency through technology," single-use sealed consumables, technology-enabled collection tracking
- Self-reported scale claims: 1M+ patient samples processed, 80+ labs/healthcare providers served, 1,000+ vehicle fleet, 10,000+ daily collections
- Registered as a DPIIT-recognized startup
- Employee count ~126
Directors
ConfirmedConfirmed (2 sources — Tofler and TheCompanyCheck agree on names and DINs):
| Name | DIN | Role | Appointed |
|---|---|---|---|
| Amit Kumar Sinha | 08065942 | - | 26 Feb 2021 |
| Nitin Kumar Reja | 09082761 | - | 26 Feb 2021 |
| Michael Reitermann | 09164064 | - | 04 May 2021 |
Financials
Partial / conflicting| FY2022-23 (year ended 31 Mar 2023) | Revenue band "₹1 Cr – 100 Cr"; YoY Total Revenue +266.72%, Net Worth +450.33%, Total Assets +349.54% (standalone; consolidated not disclosed separately) |
|---|---|
| FY2024-25 | Revenue ₹56.84 Cr, up 211% YoY |
EBITDA, PAT, exact net worth, and total borrowings: not obtained (locked behind premium/PRO tiers on both sources). No secured borrowings/charges registered with RoC.
Charges / Loans
ConfirmedNo registered charges — "As per information available, the company has no registered charges" / no secured borrowings with RoC.
Legal (Indian Kanoon)
Confirmed- Confirmed — none found
- Indian Kanoon search for "Gosamplify Private Limited" returned "No matching results," indicating no reported case law, tribunal orders, or litigation on record as of this check
Competitors
Partial / conflictingNamed peers in home diagnostics sample-collection logistics / phlebotomy-at-home space (rough scale tags, not independently verified for this pass):
- Redcliffe Labs — large-scale diagnostics chain with home collection, national scale (larger than Gosamplify)
- Orange Health Labs — VC-funded rapid home-diagnostics/logistics player, comparable/larger scale, funded startup
- Healthians — established home-collection diagnostics platform, national scale
- Thyrocare (home collection arm) — large listed diagnostics chain, much larger scale
- 1mg / Tata 1mg Labs (home collection) — large consumer health platform, much larger scale
- Portea Medical (home healthcare/sample logistics adjacent) — comparable-to-larger home-health logistics player
these are inferred industry peers based on the confirmed business model (home sample collection logistics), not sourced from a single comparator list.
Frequently Asked Questions
What does Gosamplify Private Limited do?
What is the CIN of Gosamplify Private Limited?
Where is Gosamplify Private Limited registered?
When was Gosamplify Private Limited incorporated?
Explore on Recur Club
Bharat Ke Super Founders
Recur Club's show spotlighting the founders building India's next generation of companies. Watch their stories.
Looking for business funding?
Recur Club is India's largest AI-native debt platform - working capital, term loans and structured debt from 150+ lending partners, without diluting equity.